The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Growth In Market Value Is Anticipated For The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Between 2026 And 2030?
The ribonucleic acid (rna)-based oncolytic therapy market size has experienced rapid growth in recent years. This market is projected to expand from $2.12 billion in 2025 to $2.51 billion in 2026, achieving a compound annual growth rate (CAGR) of 18.7%. The historical growth of the market can be attributed to several factors, including advancements in cancer virology research, a deeper understanding of tumor immunology, the presence of clinical trial infrastructure, increased funding for oncology research, and the initial positive results from oncolytic virus studies.
The ribonucleic acid (rna)-based oncolytic therapy market is projected for significant expansion over the coming years. This market is set to reach $4.94 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 18.4%. Factors contributing to this anticipated growth include a rise in approvals for rna-based cancer treatments, increasing demand for tailored oncology solutions, the broadening of immuno-oncology research and development pipelines, escalating investments in gene and cell therapies, and advancements in rna delivery technologies. Key trends observed during this period are the progressive development of rna virus engineering, a greater uptake of combination oncolytic approaches, an intensified emphasis on activating the immune system, the broadening scope of targeted tumor-specific rna therapies, and improved integration of precision oncology instruments.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28321&type=smp
Which Strategic Drivers Are Supporting The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Development?
The increasing embrace of personalized medicine is anticipated to fuel the expansion of the RNA-based oncolytic therapy market moving forward. Personalized medicine involves medical interventions specifically tailored to an individual’s unique genetic makeup, leading to enhanced effectiveness and fewer negative reactions. The adoption of personalized medicine is on the rise as a greater number of healthcare providers and institutions acknowledge its capacity to improve patient results through precise diagnostics and targeted therapies. RNA-based oncolytic therapy plays a vital role in cancer care by aligning with this trend towards personalized medicine to provide patient-specific and targeted treatment approaches. For instance, in February 2024, the Personalized Medicine Coalition, a US-based advocacy group for tailored medical treatments, announced that the FDA sanctioned 16 novel personalized treatments for rare disease patients in 2023, an increase from 6 in 2022. Consequently, the rising acceptance of personalized medicine is propelling the RNA-based oncolytic therapy market.
Which Segment Divisions Form The Structure Of The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market?
The ribonucleic acid (rna)-based oncolytic therapy market covered in this report is segmented –
1) By Therapy Type: Messenger Ribonucleic Acid (mRNA)-Based Oncolytic Therapy, Small Interfering Ribonucleic Acid (siRNA)-Based Oncolytic Therapy, Micro Ribonucleic Acid (miRNA)-Based Oncolytic Therapy, Other Therapy Types
2) By Route Of Administration: Intravenous, Intratumoral, Other Route Of Administrations
3) By Application: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Other Applications
4) By End-User: Hospitals, Cancer Research Institutes, Specialty Clinics, Other End-Users
Subsegments:
1) By Messenger Ribonucleic Acid (mRNA)-Based Oncolytic Therapy: Self-Amplifying mRNA (saRNA), Non-Replicating mRNA, Circular RNA (circRNA)-Based mRNA therapy
2) By Small Interfering Ribonucleic Acid (siRNA)-Based Oncolytic Therapy: Chemically Modified siRNA, Nanoparticle-Delivered siRNA, Conjugated siRNA
3) By Micro Ribonucleic Acid (miRNA)-Based Oncolytic Therapy: miRNA Mimics, miRNA Inhibitors (Antagomirs), miRNA Aponges Or Decoys
4) By Other Therapy Types: Long Non-Coding RNA (lncRNA)-Based Therapies, Short Hairpin RNA (shRNA)-Based Therapies, Aptamer-RNA Based Oncolytic Agents
What Trends Are Driving Changes In The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market?
Leading companies in the ribonucleic acid (RNA)-based oncolytic therapy market are dedicated to advancing technologies, such as synthetic messenger RNA (mRNA) technology. Their goal is to improve tumor-targeting efficacy, enhance immune activation, and deliver more precise and durable outcomes for cancer treatment. Synthetic messenger RNA (mRNA) technology functions as a biotechnology method that designs and delivers laboratory-produced mRNA sequences to direct cells in manufacturing specific therapeutic proteins for disease management, including cancer. As an illustration, in June 2024, CSPC Pharmaceutical Group Limited, a pharmaceutical company located in China, received regulatory approval in China to begin clinical trials for SYS6020, its synthetic mRNA-based cancer cell therapy. This development signifies a substantial stride in the country’s messenger RNA therapeutics landscape. SYS6020 employs mRNA-lipid nanoparticle technology to specifically target and eradicate myeloma cancer cells with minimal adverse reactions, while also demonstrating potential utility in treating certain autoimmune diseases.
Which Companies Are Engaged In The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Environment?
Major companies operating in the ribonucleic acid (rna)-based oncolytic therapy market are AstraZeneca PLC, Moderna Inc., BioNTech SE, Gritstone Bio Inc., Orna Therapeutics Inc., Strand Therapeutics Inc., Oncolytics Biotech Inc., Anima Biotech Inc., eTheRNA immunotherapies NV, Vyriad Inc., Haya Therapeutics Inc., Virogin Biotech Inc., Providence Therapeutics Holdings Inc., Sirnaomics Inc., Humane Genomics Inc., Replicate Bioscience Inc., Abogen Biosciences Inc., Chimeron Bio Inc., Aro Biotherapeutics Inc., TransCode Therapeutics Inc.
Access The Complete Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Report:
Which Region Contributes The Most To The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market?
North America was the largest region in the ribonucleic acid (RNA)-based oncolytic therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ribonucleic acid (rna)-based oncolytic therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=28321&type=smp
Browse Through More Reports Similar to the Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market 2026, By The Business Research Company
Ribose Nucleic Acid Rna Based Therapeutics Market Report 2026
Oncolytic Virus Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/oncolytic-virus-therapy-global-market-report
Nucleic Acid Based Gene Therapy Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model